Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer type with an extremely poor prognosis. Despite appropriate treatment, which includes surgery, radiotherapy, and chemotherapy, this cancer is invariably fatal. CXCR4 is the receptor for the stromal cell-derived factor-1 (SDF-1)/CXCL12 chemokine and it is expressed in a variety of solid tumors, including papillary thyroid carcinoma. Here, we show that ATC cell lines overexpress CXCR4, both at the level of mRNA and protein. Furthermore, we found that CXCR4 was overexpressed in ATC clinical samples, with respect to normal thyroid tissues by real-time PCR and immunohistochemistry. Treatment of ATC cells with SDF-1 induced proliferation and increase in phosphorylation of extracellular signal-regulated kinases and protein kinase B/AKT. These effects were blocked by the specific CXCR4 antagonist AMD3100 and by CXCR4 RNA interference. Moreover, AMD3100 effectively reduced tumor growth in nude mice inoculated with different ATC cells. Thus, we suggest that CXCR4 targeting is a novel potential strategy in the treatment of human ATC.

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer / DE FALCO, V; Guarino, V; Avilla, Elvira; Castellone, Md; Salerno, P; Salvatore, G; Faviana, P; Basolo, F; Santoro, Massimo; Melillo, ROSA MARINA. - In: CANCER RESEARCH. - ISSN 0008-5472. - STAMPA. - 67:24(2007), pp. 11821-11829. [10.1158/0008-5472.CAN-07-0899]

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer

AVILLA, ELVIRA;SANTORO, MASSIMO;MELILLO, ROSA MARINA
2007

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer type with an extremely poor prognosis. Despite appropriate treatment, which includes surgery, radiotherapy, and chemotherapy, this cancer is invariably fatal. CXCR4 is the receptor for the stromal cell-derived factor-1 (SDF-1)/CXCL12 chemokine and it is expressed in a variety of solid tumors, including papillary thyroid carcinoma. Here, we show that ATC cell lines overexpress CXCR4, both at the level of mRNA and protein. Furthermore, we found that CXCR4 was overexpressed in ATC clinical samples, with respect to normal thyroid tissues by real-time PCR and immunohistochemistry. Treatment of ATC cells with SDF-1 induced proliferation and increase in phosphorylation of extracellular signal-regulated kinases and protein kinase B/AKT. These effects were blocked by the specific CXCR4 antagonist AMD3100 and by CXCR4 RNA interference. Moreover, AMD3100 effectively reduced tumor growth in nude mice inoculated with different ATC cells. Thus, we suggest that CXCR4 targeting is a novel potential strategy in the treatment of human ATC.
2007
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer / DE FALCO, V; Guarino, V; Avilla, Elvira; Castellone, Md; Salerno, P; Salvatore, G; Faviana, P; Basolo, F; Santoro, Massimo; Melillo, ROSA MARINA. - In: CANCER RESEARCH. - ISSN 0008-5472. - STAMPA. - 67:24(2007), pp. 11821-11829. [10.1158/0008-5472.CAN-07-0899]
File in questo prodotto:
File Dimensione Formato  
Can res 2007.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 521.67 kB
Formato Adobe PDF
521.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/106343
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 96
  • ???jsp.display-item.citation.isi??? 90
social impact